Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Myvac

First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy

20210121 TG4050 1st patient HNSCC EN

Published 21 January 2021
Categorized as 2021, Myvac, Press release, TG4050

Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers

20201006 Transgene_NEC_BostonGene_Press_Release_final

Published 6 October 2020
Categorized as 2020, Myvac, Press release, TG4050

Transgene and Hypertrust Patient Data Care announce successful go-live of the world’s first blockchain solution for clinical trials of personalized healthcare

20200709 PR Hypertrust Transgene EN

Published 9 July 2020
Categorized as 2020, Myvac, Press release, TG4050

Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine

AACR2020 myvac B. Mallone et al. AACR 2020 Download the poster here Poster Presentation

Published 22 June 2020
Categorized as 2020, Myvac, Publication, publication key en, TG4050

Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020

20200622a – Transgene PR AACR 3 posters

Published 22 June 2020
Categorized as 2020, BT-001, Invir.IO, Myvac, Press release

Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050

20200515_AACR myvac curtain raiser EN

Published 15 May 2020
Categorized as 2020, Myvac, Press release, TG4050

Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac® Individualized Immunotherapy TG4050

20190916 PR ANSM TG4050 EN

Published 16 September 2019
Categorized as 2019, Myvac, Press release, TG4050

Transgene Receives MHRA Approval for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK

20190710 PR MHRA TG4050 EN

Published 10 July 2019
Categorized as 2019, Myvac, Press release, TG4050

Transgene receives FDA IND Clearance for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer

20190513 PR IND TG4050 EN

Published 13 May 2019
Categorized as 2019, Myvac, Press release, TG4050

Transgene to start clinical development of lead myvac® individualized immunotherapy, TG4050, in 2019, under its partnership with NEC

20190305-PR-NEC-Agreement-US-1

Published 5 March 2019
Categorized as 2019, Myvac, Press release, TG4050

Posts pagination

Newer posts Page 1 … Page 6 Page 7 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu